BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 26138345)

  • 1. Ixazomib for the treatment of multiple myeloma.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
    Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
    Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
    Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral ixazomib maintenance therapy in multiple myeloma.
    Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
    Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
    Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
    Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixazomib in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixazomib - the first oral proteasome inhibitor.
    Xie J; Wan N; Liang Z; Zhang T; Jiang J
    Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of ixazomib for the treatment of multiple myeloma.
    Bonnet A; Moreau P
    Expert Opin Drug Saf; 2017 Aug; 16(8):973-980. PubMed ID: 28661711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixazomib: First Global Approval.
    Shirley M
    Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixazomib for the treatment of multiple myeloma.
    Richardson PG; Zweegman S; O'Donnell EK; Laubach JP; Raje N; Voorhees P; Ferrari RH; Skacel T; Kumar SK; Lonial S
    Expert Opin Pharmacother; 2018 Dec; 19(17):1949-1968. PubMed ID: 30422008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO
    Machida M; Fukunaga S; Hara T
    Nihon Yakurigaku Zasshi; 2018; 151(4):166-178. PubMed ID: 29628465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixazomib: a novel drug for multiple myeloma.
    Zanwar S; Abeykoon JP; Kapoor P
    Expert Rev Hematol; 2018 Oct; 11(10):761-771. PubMed ID: 30173621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
    Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
    Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
    Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
    Fogli S; Galimberti S; Gori V; Del Re M; Danesi R
    Pharmacol Res; 2021 May; 167():105537. PubMed ID: 33684510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Al-Salama ZT; Garnock-Jones KP; Scott LJ
    Target Oncol; 2017 Aug; 12(4):535-542. PubMed ID: 28660423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
    Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
    Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
    Voorhees PM; Suman VJ; Tuchman SA; Laubach JP; Hassoun H; Efebera YA; Mulkey F; Bova-Solem M; Santo K; Carlisle D; McCarthy PL; Richardson PG
    Am J Hematol; 2021 Dec; 96(12):1595-1603. PubMed ID: 34559902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.